key: cord-1001815-0okdb40a authors: Poehler, M.; Gibson, L.; Lustig, A.; Moreland, N. J.; McGregor, R.; James, A. title: Estimating decay curves of neutralising antibodies to SARS-CoV-2 infection date: 2021-06-15 journal: nan DOI: 10.1101/2021.06.13.21258857 sha: ef5ec4e93d555797ee41db2b2de02db7f1991d95 doc_id: 1001815 cord_uid: 0okdb40a Estimating the longevity of an individual's immune response to the Sars-Cov-2 virus is vital for future planning, particularly of vaccine requirements. Neutralising antibodies (Nabs) are increasingly being recognised as a correlate of protection and whilst there are many studies which follow the response of a cohort of people, each study alone is not enough to predict the long term response. Studies use different assays to measure Nabs making them hard to combine. We present a modelling method which can combine multiple datasets and can be updated as more detailed data becomes available. Combining data from six published datasets we predict that after a short period of rapid decay the half-life of the NAb response is approximately one year giving optimism that the response will be long-lived. As the first waves of Sars-CoV-2 recede a key question in containing the pandemic is the 26 longevity of an individual's immune response to both vaccines and naturally acquired 27 immunity. As of April 27 th 2021, less than 18 months after the virus was first seen, 1.06 billion 28 doses had been given to over 500 million people. About 7.3% of the world's population had 29 received at least one dose. However, these figures hide the inequity of the distribution -three- 30 quarters of these doses have been received by people in just 10 nations, leaving the remainder 31 spread across the other 170 nations (Kreier, 2021) . As second waves of the virus spread 32 across many nations, particularly those with very low vaccination rates like Brazil and India, 33 the need to understand both the body's natural immune response and the vaccine driven 34 response becomes increasingly important. Especially the answer to the key question -How 35 long will immunity last? 36 New datasets are constantly being released that measure SARS-CoV-2 neutralising 37 antibodies (Nabs): a widely discussed correlate of protection. High titres of Nabs are positively 38 correlated with protection against SARS-CoV-2 challenge in animal models (Chandrashekar 39 et al., 2020) and the presence of neutralising antibodies protected a small number of 40 individuals from re-infection during a SARS-CoV-2 outbreak on a fishing vessel (Addetia et 41 al., 2020). (Khoury et al., 2021) used in vitro NAb data generated from individuals vaccinated 42 or infected with SARS-CoV-2 to show neutralisation levels are highly predictive of immune 43 protection. However, the difficulties posed by combining data generated from assays with 44 different methodologies was highlighted in this modelling study. 45 Collecting data on an individual's Nabs levels over time is challenging. It may take years for 46 levels to decrease and a wide variation is expected across individuals (Seow et al., 2020) . 47 Coupled with this is the dynamics of the response itself. After infection or vaccination Nabs 48 levels tend to increase to a peak then drop slowly. The height of the peak is correlated with 49 the severity of infection (Seow et al., 2020) and can vary by orders of magnitude (Ripperger 50 et al., 2020). Similarly, the timing of the peak may also show a wide range of variation and a 51 delay in Nab production is associated with disease severity (Lucas et al., 2021) . Whether the 52 decay rate is also correlated to the disease severity is as yet unknown for SARS-CoV-2. 53 Models can help in understanding the behaviour of the response but with such wide variation 54 between individuals robust methods are needed to make the most of data which currently is 55 still close to the infection date for almost all individuals and, even as time progresses, will 56 require extensive longitudinal follow up of many individuals to get comprehensive data. 57 Here we describe a method, which normalises each individuals' response, so the data can be 58 pooled to give a more robust estimate of the decay portion of the response. We start by 59 predicting the antibody response peak for each individual. We compare four response curves 60 and choose the best fit which uses a kinetic response curve. After using the fitted response 61 curve to predict the peak response (time and magnitude) for every individual in the dataset we 62 then normalise each individuals' response around their personal predicted peak. This allows 63 all data collected after the peak response to be pooled for every individual in the dataset. We 64 fit a decay function to the pooled data give a robust estimate of the longevity of the immune 65 response. 66 Our kinetic response curve for the antibody response has three independent parameters which 67 allow the three key points of the curve: peak timing, peak strength and long term decay rate 68 to be independent. The method can be upgraded to use a more complex response curve at 69 this point, for example to distinguish between the two routes to immunity, vaccination and 70 naturally acquired infection, with subtle differences in the shapes of the response curve. At 71 this stage data following up a large cohort of individuals over many months is not yet available, 72 hence our choice of a very simple response curve which captures the phenomenology of the 73 response and can be used on more sparse datasets. 74 To estimate the longevity of the Nabs response we compare two very simple decay functions: 75 a single exponential decay and a two-step exponential decay. 76 We apply our method to six published datasets and compare our results to the published 77 findings. As the method normalises the response data it has a final advantage: data collected 78 using different assays can be collated. This is done under the assumption that the decay 79 function for every individual has the same shape and simply differs in the scale. As further and 80 more detailed data is collected this assumption can be tested. showed that the response is similar to that from other acute viral infections, i.e. it shows an 86 initial peak before decaying and the size of the peak is dependent on disease severity. The 87 original work split the group into general cases (labelled Seow here) which included some 88 severe infections, and health care workers (labelled Seow (HCW) here) which predominantly 89 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Data from individuals with less than 3 measurements at unique time points were excluded. 96 When multiple replicates on a single day were available the mean value was used. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint role in this case but we would expect the overall antibody response to have a similar shape, 175 i.e. an initial increase which slows as it reaches a peak before decaying exponentially. In this 176 respect the simplicity of the presented response curve is a strength that allows it to give 177 reasonable results despite a different mechanism. 178 We fit our four candidate response curves to each individual Nabs time series with at least 179 three unique data points. All response curves were fitted using Matlab 2018b lsqcurvefit. Table S1 . In the full results we report the 183 maximum inhibition as predicted by each response curve and the timing of the peak, the root 184 mean square error between the fitted response curve and the data for that individual. Estimating key outputs: peak size and timing 199 We report the median and bootstrapped confidence interval from 1000 samples for all four 200 curves with each dataset separately for the key outputs of peak strength and timing. Whilst it 201 is recognised that the peak size and timing of an antibody response will vary between 202 individuals a good model will include this variation but still give robust estimates of key outputs 203 that are not affected by outliers in the data. We use the size of the predicted confidence interval 204 as a measure of robustness. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint 206 To compensate for the scarcity of data we normalise each response to allow the data to be 207 pooled. This allows us to meaningfully combine data from individuals to give a more robust 208 estimation of the rate at which antibodies decay. For each model, we normalise each 209 individual's time series using the peak size and time predicted by the response curve for that 210 time series, i.e. the time series peak is shifted to • = 0 and the maximum antibody response 211 is scaled to 1 for every individual. We then fit a decay function to all the normalised data that 212 is either at or past the time series peak, i.e. during the decay phase (see Figure 1 ). Figure 1A shows all raw data past the response curve predicted peak, 222 as the data is pooled across all individuals this method can also use data from series with only 223 a single point past the peak. Figure 1B is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint rate of the data. Note that for some individuals the first data point after the peak is higher than 229 the predicted peak. 230 This method can be used with any decay function. We tested two functions: a single 231 exponential function, i.e. linear decay of the logged data, providing a simple half-life estimate 232 that can be compared to other results; and a two part exponential function (cf Wheatley et al. where there is a reasonable amount of data all the candidate response curves give very similar 252 results. However, when data is scarce, e.g. at very early or late time points, the candidate 253 curves can diverge significantly. This shows the problems with using these fitted curves to 254 directly predict the long term behaviour of the response. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint Table 269 S1 for details. Peak inhibition (Whitcombe data only) was of the order 100% and predicted to 270 peak at approximately 20 days post onset of symptoms (kinetic curve). For all other datasets, 271 using the kinetic curve, neutralizing antibody titre was shown to peak between day 18 and day 272 30 after onset at which point median peak titre was between 150 (Wheatley) and 4,800 273 (Seow) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint Choosing the best fit response curve 282 There was no single response curve that was the best fit to the majority of time series (see 283 Table S1 for detailed results). Of the 153 time series fitted the kinetic response curve was the 284 best fit (measured by smallest RMSE) most often (38%) followed by the Weibull response 285 curve (28%). However this varied across datasets. In the Iyer, Lau and Seow (non-HCW) 286 datasets the kinetic response curve fitted best in the majority of cases, whereas in the 287 Wheatley dataset the gamma function was most frequently the best fit and in the Whitcombe 288 data the Weibull was the best fit most often. Gamma function consistently gave very high and unrealistic estimates of the peak antibody 295 response. It also frequently predicted the peak response to occur either before symptom onset 296 or more than 250 days post symptom onset. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint When we analysed the choice of best fit response curve using both multinomial and logistic 298 regression the only significant variable was the length of the time series. Only very short time 299 series (three points or less) had an inconclusive best fit -the Weibull and Gamma series were 300 almost equally likely in this case. For a series with at least four points the best response curve 301 was the kinetic one. The probability of the kinetic response curve fitting a time series with 4 302 points best was 37%, this increased to 82% for a series with 7 points. A logistic regression 303 model where the response variable is either the kinetic response curve is the best fit or any of 304 the statistical response curve is the best fit shows the same result and also predicts that 305 dataset is not a significant variable and the timing of the data collection, i.e. samples were 306 taken either all before the antibody response peak or samples were taken more than 90 days 307 post onset of symptoms, is also not significant. Subsequent analysis was carried out using the 308 kinetic response curve. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint One dataset (Lau) showed no significant decay after the predicted antibody peak and 315 correspondingly unrealistic half-life estimates (see Table 2 ). Contrastingly, both datasets by 316 Seow showed high predictive power (• • = 0.52,0.42(•••)). 317 An advantage of the pooled method is that data from different Nabs assays can be collated Using a two-step decay function gave more consistent results in our study. Only one dataset, 331 Whitcombe, did not show a change in decay rate, which may be due to this dataset containing 332 mostly late stage data. The median time to switch from fast to slow decay was 19 days after 333 the peak response and the median half-lives for the fast and slow stages respectively were 23 334 days and 62 days. When the data sets were analysed together the results were even more 335 optimistic showing a fast stage which lasted for 17 days post peak response with half-life of 336 12 days then the half-life increased to 345 days. This implies that one and two years after 337 infection antibodies would be at approximately 23% and 11% of their maximum level 338 respectively. This is a highly encouraging result and if vaccine immunity follows a similar 339 pattern it gives hope that yearly or even two-yearly booster immunisations could be sufficient 340 to provide long-lasting immunity. 341 Although our method is tested here with antibody data from individuals who have been 342 infected, it will also be useful for predicting antibody levels after vaccination. The underlying 343 antibody response curve can be updated as more comprehensive datasets become available. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 15, 2021. ; https://doi.org/10.1101/2021.06.13.21258857 doi: medRxiv preprint The biggest assumption of the method presented here is that individuals with a very strong 345 response to the virus will have a similar decay rate as an individual with a much weaker 346 response. More detailed data to test this assumption would allow for a better understanding 347 of the longevity of the immune response. It would also allow for a more detailed understanding 348 of the variation seen between individuals. 349 The key advantage of the pooled method applied here is the power to combine data from 350 many individuals whilst accounting for the initial increasing phase of the antibody response. 351 As data sets become larger the principle of fitting a simple response curve to predict the 352 antibody peak then normalising the decay phase data against the peak will allow a range of 353 candidates to be tested for the shape of the decay function. 354 Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during 361 a fishery vessel outbreak with a high attack rate SARS-CoV-2, SARS-CoV, 364 and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a 365 systematic review and meta-analysis SARS-CoV-2 infection protects against rechallenge in rhesus macaques Dynamics and significance of the antibody response to SARS-CoV-2 infection Neutralizing antibody levels are highly predictive of immune protection from 374 symptomatic SARS-CoV-2 infection Unprecedented achievement': who received the first billion COVID vaccinations? 376 Nature Neutralizing antibody titres in SARS-CoV-2 infections Delayed 380 production of neutralizing antibodies correlates with fatal COVID-19 Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence 383 communities and reveal durable humoral immunity Longitudinal observation and decline of neutralizing antibody responses in the three months 386 following SARS-CoV-2 infection in humans Dynamic models of immune 388 responses: what is the ideal level of detail? Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand